ALXA Share Price

Open 0.00 Change Price %
High 0.00 1 Day 0.00 0.00
Low 0.00 1 Week 0.00 0.00
Close 0.94 1 Month 0.00 0.00
Volume 100 1 Year 0.35 59.32
52 Week High 1.03
52 Week Low 0.00
ALXA Important Levels
Resistance 2 0.94
Resistance 1 0.94
Pivot 0.31
Support 1 0.94
Support 2 0.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA)

ALXA Technical Analysis 4
As on 20th Jun 2016 ALXA Share Price closed @ 0.94 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.85 & Strong Buy for SHORT-TERM with Stoploss of 0.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALXA Target for April
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ALXA Other Details
Segment EQ
Market Capital 64712160.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website
ALXA Address
2091 Stierlin Court
Mountain View, CA 94043
United States
Phone: 650-944-7000
ALXA Latest News
Delisting of Securities of Alexza Pharmaceuticals, Inc. from The Nasdaq Stock ...   PR Newswire (press release)   - 02nd Jul 16
Alexza Pharmaceuticals Acquired by Ferrer   PR Newswire (press release)   - 21st Jun 16
ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie ...   Business Wire (press release)   - 16th May 16
Alexza Pharmaceuticals to be Acquired by Ferrer   PR Newswire (press release)   - 10th May 16
Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter of Intent   PR Newswire (press release)   - 27th Feb 16
Alexza Pharmaceuticals Reacquires US Commercial Rights for ADASUVE® (loxapine ...   PR Newswire (press release)   - 24th Feb 16
Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ ...   PR Newswire (press release)   - 22nd Dec 15
Alexza and Teva part ways on ADASUVE   Seeking Alpha   - 02nd Nov 15
Ferrer and Alexza Pharmaceuticals Provide Update on ADASUVE® European and ...   PR Newswire (press release)   - 14th Oct 15
Alexza and Ferrer Expand ADASUVE® Partnership   PR Newswire (press release)   - 27th Oct 14
Interactive Technical Analysis Chart Alexza Pharmaceuticals, Inc. ( ALXA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Alexza Pharmaceuticals, Inc.
ALXA Business Profile
Alexza Pharmaceuticals, Inc. (Alexza), incorporated on December 19, 2000, is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. As of December 31, 2011, the Company had screened more than 400 drug compounds, identifying approximately 200 drug compounds that demonstrate initial vaporization. The Company's product candidate is ADASUVE (Staccato loxapine). Its other product candidates in active development are AZ-007 (Staccato zaleplon) and Staccato nicotine. Its product candidates not in active development are AZ-104 (Staccato loxapine, low-dose), AZ-002 (Staccato alprazolam) and AZ-003 (Staccato fentanyl). In January 2011, Cypress was acquired by Royalty Pharma. Alexza is developing ADASUVE for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. In August 2011, the Company resubmitted the ADASUVE NDA, which was accepted for filing by the Food and Drug Administration (FDA) as a complete, class 2 response to the FDA's CRL. The FDA indicated a Prescription Drug User Fee Act (PDUFA), goal date for the ADASUVE NDA of February 4, 2012. The Company has completed Phase I testing for AZ-007. This product candidate is being developed for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. In the Phase I study, AZ-007 delivered an IV-like pharmacokinetic profile with a median time to peak drug concentration of 1.6 minutes. During the year ended December 31, 2011, it completed the process development work to transfer AZ-007 from its original single-dose clinical product device to the current single-dose commercial product device.